Dazucorilant
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Dazucorilant
- Molecular weight
- 582.58
- Structure (SMILES)
- O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2
- cort 113176
- CORT-113176
- cort113176
- Cort113176
- CORT113176
- dazucorilant
- Dazucorilant
- dazucorilant [INN]
- DAZUCORILANT [USAN]
- Dazucorilant 150 mg
- Dazucorilant 300 mg
- dazucorilant inn
- dazucorilant usan
- CAS registry numbers
- 1496508-34-9
- ChEMBL ID
- CHEMBL3734774
- InChIKey
- VXOBXKQLNWYQPQ-NDEPHWFRSA-N
- PubChem compound IDs
- 72192163
- FDA ingredient codes (UNII)
- HR4RD5RBJ6
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- dazucorilant
- Type
- Synthetic organic
- Drug name stem
- -corilant
Mechanisms of action
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 9.55
- Affinity units
- pKi
Investigated indications
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
Open Targets indications
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 85.16
- Calculated partition coefficient (ALogP)
- 5.33
- Calculated partition coefficient (XLogP)
- 4.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 41
- Molecular formula
- C29H22F4N4O3S
- Monoisotopic mass
- 582.13487440
- Natural product
- No
- Recorded assays
- 23
- Active assays
- 11
Active assay types
- Confirmatory
Cardiac potassium channel inhibition
- Median
- 5,000
- Mean
- 5,000
- Minimum
- 5,000
- Maximum
- 5,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Liver toxicity assay
- Median
- 280
- Mean
- 551.6
- Minimum
- 13
- Maximum
- 1,600
- Unit
- nM
- Assays
- 5
- Standard deviation
- 654.309
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- EC50
- Ki
Oral bioavailability
- Median
- 31
- Mean
- 31
- Minimum
- 31
- Maximum
- 31
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (6)
- Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
- Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
- Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants
- Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
- Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants
In development for (1)
- Amyotrophic lateral sclerosis Phase 1